Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Vertex Pharmaceuticals (VRTX)

Vertex shareholders elect 10 directors, approve 2026 stock plan

Neutral Impact 2 of 5 shareholder Written later

At its May 13, 2026 annual meeting, Vertex shareholders re-elected a 10-member board, ratified Ernst & Young LLP as auditor for 2026, and approved the 2026 Stock and Option Plan, which replaces the 2013 plan. A shareholder proposal on the right to act by written consent also passed, with 126,892,696 votes for and 95,756,148 against.

Key points

  • Proposal 4: 2026 Stock and Option Plan approved with 216,097,268 for and 6,523,460 against
  • Proposal 5: shareholder proposal on the right to act by written consent approved with 126,892,696 for and 95,756,148 against
  • Proposal 3: advisory vote on 2025 executive pay approved with 207,918,843 for and 14,522,776 against
  • Proposal 2: Ernst & Young LLP ratified as independent auditor for the year ending December 31, 2026 with 223,514,070 for

The filing

CompanyVertex Pharmaceuticals (VRTX)
Form8-K, current report
Filed with the SECMay 13, 2026, 4:03 PM ET
Accession number0000875320-26-000204

Items reported: 5.02 Director / Officer Change5.07 Shareholder Vote Results

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 2:16 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.